Sign In
Buy REPL
$9.98
+1.11 (+12.51%)
At Close: Jun 03, 2026
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
07:00am, Monday, 20'th Oct 2025
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
08:00am, Sunday, 19'th Oct 2025
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options If you are a long-term
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
12:11pm, Wednesday, 24'th Sep 2025
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).
Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL
03:47pm, Monday, 22'nd Sep 2025
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities la
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
02:24pm, Monday, 22'nd Sep 2025
NEW YORK--(BUSINESS WIRE)---- $REPL #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL
05:35am, Monday, 22'nd Sep 2025
LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL ) violations of
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
04:21am, Monday, 22'nd Sep 2025
LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune
NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
07:40am, Sunday, 21'st Sep 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024
